First things first: Tirzepatide is an active ingredient, whereas Ozempic is a branded medication
Zepbound : Approved for chronic weight management (BMI 30 kg/m or 27 kg/m with a weight-related condition like high blood pressure or OSA) and moderate to severe OSA in adults with obesity
Patients should be counseled on warning signs including inability to tolerate oral fluids, decreased urine output, dizziness, or severe abdominal pain, which require immediate medical evaluation rather than dose escalation
Researchers describe this as a quiet liberation
The investigational status of retatrutide and the limited population size of pre-Phase-3 trials mean less is known about long-term and rare adverse events than for FDA-approved tirzepatide or semaglutide
Tirzepatide may be suitable for adults who are classified as obese, with a body mass index (BMI) of 30 or higher, or those who are overweight with a BMI of 27 or higher and have related health conditions such as hypertension, type 2 diabetes, or dyslipidemia
